Eupraxia Pharmaceuticals
Stock Forecast, Prediction & Price Target

Eupraxia Pharmaceuticals Financial Estimates

Eupraxia Pharmaceuticals Revenue Estimates

Eupraxia Pharmaceuticals EBITDA Estimates

Eupraxia Pharmaceuticals Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
CA$0
 
N/A
CA$0
 
0%
CA$0
 
0%
Avg: CA$45.54M
Low: CA$45.54M
High: CA$45.54M
avg. 0%
Avg: CA$32.97M
Low: CA$32.97M
High: CA$32.97M
avg. -27.59%
Avg: CA$79.08M
Low: CA$79.08M
High: CA$79.08M
avg. 139.85%
Avg: CA$32.09M
Low: CA$32.09M
High: CA$32.09M
avg. -59.41%
Net Income
 
% change YoY
CA$-22.98M
 
N/A
CA$-23.25M
 
-1.17%
CA$-37.39M
 
-60.75%
Avg: CA$-23.04M
Low: CA$-23.04M
High: CA$-23.04M
avg. 38.36%
Avg: CA$-7.90M
Low: CA$-7.90M
High: CA$-7.90M
avg. 65.71%
Avg: CA$9.54M
Low: CA$9.54M
High: CA$9.54M
avg. 220.83%
Avg: CA$-6.58M
Low: CA$-6.58M
High: CA$-6.58M
avg. -168.96%
EBITDA
 
% change YoY
CA$-20.76M
 
N/A
CA$-22.44M
 
-8.09%
CA$-37.39M
 
-66.63%
Avg: CA$0
Low: CA$0
High: CA$0
avg. 100%
Avg: CA$0
Low: CA$0
High: CA$0
avg. 0%
Avg: CA$0
Low: CA$0
High: CA$0
avg. 0%
Avg: CA$0
Low: CA$0
High: CA$0
avg. 0%
EPS
 
% change YoY
-$1.61
 
N/A
-$1.21
 
24.84%
-$1.58
 
-30.57%
Avg: -$0.95
Low: -$0.95
High: -$0.95
avg. 39.58%
Avg: -$0.33
Low: -$0.33
High: -$0.33
avg. 65.71%
Avg: $0.4
Low: $0.4
High: $0.4
avg. 220.83%
Avg: -$0.27
Low: -$0.27
High: -$0.27
avg. -168.96%
Operating Expenses
 
% change YoY
CA$18.67M
 
N/A
CA$23.20M
 
24.23%
CA$37.92M
 
63.43%
Avg: CA$0
Low: CA$0
High: CA$0
avg. -100%
Avg: CA$0
Low: CA$0
High: CA$0
avg. 0%
Avg: CA$0
Low: CA$0
High: CA$0
avg. 0%
Avg: CA$0
Low: CA$0
High: CA$0
avg. 0%

FAQ

What is Eupraxia Pharmaceuticals stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 38.98% in 2025-2028.

We have gathered data from 1 analysts. Their low estimate is -23.04M, average is -23.04M and high is -23.04M.

What is Eupraxia Pharmaceuticals stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 13.21% in 2025-2028.

We have gathered data from 2 analysts. Their low revenue estimate is CA$45.54M, average is CA$45.54M and high is CA$45.54M.

What is Eupraxia Pharmaceuticals stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 39.29% in 2025-2028.

We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.95, average is -$0.95 and high is CA$-0.95.